A placebo-controlled, double-blind study of sucralfate in the short-term treatment of duodenal ulcer.
Seventy-six outpatients with endoscopically proven duodenal ulcer were entered into a double-blind, randomized, placebo-controlled study to assess the efficacy of sucralfate in ulcer healing. The patients were assigned to either sucralfate or placebo given in a dose of 2 tablets of 500 mg 4 times daily. Sixty-five patients were re-evaluated endoscopically at the end of the fourth week of treatment. Complete healing was observed in 24 of the 33 patients (72.7%) on sucralfate and 8 of 32 patients (25.0%) on placebo (Fisher's exact test; p = 0.0003). The improvement of subjective symptoms and the amount of antacid consumed were similar in the two groups. No serious side effects were noted.
D000328:Adult; D000535:Aluminum / Q000009:adverse effects / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy*; D004384:Duodenoscopy; D005260:Female; D006801:Humans; D008297:Male; D011897:Random Allocation; D013392:Sucralfate
D000897:Anti-Ulcer Agents; D013392:Sucralfate; D000535:Aluminum